JDRF Statement on the FDA Clearance of t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology for children age 6 and older

“Today’s clearance by the U.S. Food and Drug Administration (FDA) extending the pediatric indication of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology is another big win for the T1D community and especially for our youngest members. With this technology now available to children ages six and above, families have an additional option to explore as they seek to find the system that best suits their needs.

As part of our mission to improve the lives of those affected by T1D, JDRF has been a leader in artificial pancreas (AP) research for more than 15 years and partnered with the FDA to establish regulatory pathways to ensure AP technology gets into the hands of the T1D community.

Until we find cures, we are continuing to support the development of new technologies and treatments to improve blood sugar management so people with T1D can live healthier and more manageable lives. JDRF is also fighting to ensure people with this disease have more choices and better access to the diabetes management tools that work best for them through our Coverage2Control campaign. Today’s announcement is yet another reason why health plans should cover all FDA authorized diabetes management tools to help people with T1D manage this life-threatening disease.”

About JDRF

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit www.jdrf.org or follow us on Twitter: @JDRF